Objective: To observe the efficacy and safety of cetirizine hydrochloride drops combined with fluticasone propionate inhalation in the treatment of allergic rhinitis (AR) complicated with bronchial asthma (BA) in children. Methods: A total of 84 children with AR complicated with BA admitted into our hospital from Jan. 2020 and Jun. 2022 were enrolled to be divided into the combination group and control group via the random number table method

with 42 cases in each group. The control group was treated with fluticasone propionate inhalation

while the combination group was additionally given cetirizine hydrochloride drops combined with fluticasone propionate inhalation. The scores of AR and BA severity

pulmonary function indicators such as forced expiratory volume in one second (FEV1)

peak expiratory flow (PEF)

forced vital capacity (FVC)

serum enzymes such as soluble intercellular adhesion molecule-1 (sICAM-1)

soluble vascular intercellular adhesion molecule-1 (sVCAM-1)

interleukin-4 (IL-4) and IL-10

serum amyloid protein A (SAA) before and after treatment and occurrence of adverse drug reactions were compared between two groups. Results: After treatment

scores of AR and BA severity in combination group were significantly lower than those in control group (P< 0. 05)

while levels of FEV1

PEF and FVC were significantly higher than those in control group (P<0. 05). After treatment

levels of sICAM-1

sVCAM-1

IL-4

IL-10 and SAA decreased in both groups

and the combination group was lower than control group (P< 0. 05). There was no significant difference in the incidence of adverse drug reactions between two groups (P >0. 05). Conclusion: Cetirizine hydrochloride drops combined with fluticasone propionate inhalation can significantly relieve clinical symptoms

effectively improve pulmonary function

regulate serum zymetology indicators and SAA in children with AR complicated with BA

which will not increase the incidence of adverse drug reactions.